Trials / Recruiting
RecruitingNCT06452160
A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BGC515 Capsules in Patients With Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 103 (estimated)
- Sponsor
- BridGene Biosciences Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this open-label, dose escalation and dose expansion Phase I clinical trial is to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of BGC515 administered once daily in 3 weeks cycles in solid tumor patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BGC515 | Capsules for oral administration |
Timeline
- Start date
- 2024-06-27
- Primary completion
- 2027-06-01
- Completion
- 2027-12-01
- First posted
- 2024-06-11
- Last updated
- 2024-08-09
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06452160. Inclusion in this directory is not an endorsement.